HC Wainwright & Co. Upgrades Prime Medicine to Buy, Announces $8 Price Target

HC Wainwright & Co. analyst Arthur He upgrades Prime Medicine (NASDAQ: PRME ) from Neutral to Buy and announces $8 price target.